# SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

> **NCT05293912** · PHASE1 · TERMINATED · sponsor: **Hangzhou Sumgen Biotech Co., Ltd.** · enrollment: 2 (actual)

## Conditions studied

- Hematological Malignancy
- Lymphoma

## Interventions

- **DRUG:** SG2501

## Key facts

- **NCT ID:** NCT05293912
- **Lead sponsor:** Hangzhou Sumgen Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-03
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Adjustment of clinical development plan
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05293912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05293912, "SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05293912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*